Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The market for Paroxysmal Nocturnal Hemoglobinuria PNH and Atypical Hemolytic Uremic Syndrome aHUS has seen remarkable ...

AstraZeneca’s Ultomiris shows promise in rare post-transplant complication There are currently no approved treatment options for HSCT-TMA AstraZeneca (AZ) has announced promising results from a ...

Novartis has shared positive results from a phase 3b study of Fabhalta (iptacopan) in a new population of patients with the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark. Next up, the complement inhibitor—which AZ ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Ultomiris (ravulizumab) demonstrated clinically-meaningful overall survival at 26 weeks ...

Ultomiris (ravulizumab-cwvz) is a prescription drug that treats certain rare inflammatory conditions in some people. Learn about dosage, side effects, and more.

Initiative’s growth came almost entirely from 11 existing pharma clients, including AstraZeneca, Bristol Myers Squibb, Merck and Gilead. It added work from Alexion Pharmaceuticals for Ultomiris.